AbbVie Inc. ABBV

Latest FY: 2025 Healthcare Drug Manufacturers - General
Market Price $249.34
Market Cap $443.15B
P/E Ratio 105.65
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑8.6% YoY
$61.16B
3-Yr CAGR: 1.8%
Net Income ↓-1.2% YoY
$4.23B
Net Margin: 6.9%
Free Cash Flow ↓-0.1% YoY
$17.82B
FCF Yield: 4.02%
EPS (Diluted) ↓-1.3% YoY
$2.36
Basic: $2.37
Return on Equity Efficiency
N/A
ROA: 14.5%
⚡ N/A due to negative equity (share buybacks or other)

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (ABBV)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $25,638.0M $19,805.0M $5,953.0M $3.63 $7,041.0M $6,562.0M
FY 2017 $28,216.0M +10.1% $21,176.0M $5,309.0M -10.8% $3.30 -9.1% $9,960.0M $9,431.0M +43.7%
FY 2018 $32,753.0M +16.1% $25,035.0M $5,687.0M +7.1% $3.66 +10.9% $13,427.0M $12,789.0M +35.6%
FY 2019 $33,266.0M +1.6% $25,827.0M $7,882.0M +38.6% $5.28 +44.3% $13,324.0M $12,772.0M -0.1%
FY 2020 $45,804.0M +37.7% $30,417.0M $4,616.0M -41.4% $2.72 -48.5% $17,588.0M $16,790.0M +31.5%
FY 2021 $56,197.0M +22.7% $38,751.0M $11,542.0M +150.0% $6.45 +137.1% $22,777.0M $21,990.0M +31.0%
FY 2022 $58,054.0M +3.3% $40,640.0M $11,836.0M +2.5% $6.63 +2.8% $24,943.0M $24,248.0M +10.3%
FY 2023 $54,318.0M -6.4% $33,903.0M $4,863.0M -58.9% $2.72 -59.0% $22,839.0M $22,062.0M -9.0%
FY 2024 $56,334.0M +3.7% $39,430.0M $4,278.0M -12.0% $2.39 -12.1% $18,806.0M $17,832.0M -19.2%
FY 2025 $61,160.0M +8.6% $42,956.0M $4,226.0M -1.2% $2.36 -1.3% $19,030.0M $17,816.0M -0.1%
$

Valuation

Market Price $249.34
Market Cap $443.15B
Enterprise Value $502.42B
P/E Ratio 105.65
P/B Ratio N/A
FCF Yield 4.02%
Dividend Yield 2.67%
Shares Outstanding 1,766,792,800
%

Profitability & Margins

Gross Margin 70.24%
Operating Margin 24.65%
Net Margin 6.91%
Return on Equity (ROE) N/A (Negative Equity)
Return on Assets (ROA) 14.54%
Asset Turnover 2.10x
Revenue 3-Yr CAGR 1.75%
🛡️

Financial Health & Liquidity

Current Ratio 0.67
Cash Ratio 0.12
Debt / Equity -19.726
Debt / Assets 2.219
Cash & Equivalents $5.23B
Total Debt $64.50B
Book Value / Share $-1.85
💧

Cash Flow Efficiency

Operating Cash Flow $19.03B
Capital Expenditures (CapEx) $1.21B
Free Cash Flow $17.82B
OCF / Revenue 31.12%
FCF / Revenue 29.13%
FCF 3-Yr CAGR -9.76%
🏷️

Per Share Metrics

EPS (Diluted) $2.36
EPS (Basic) $2.37
Dividends / Share $6.65
Book Value / Share $-1.85
EPS YoY Growth -1.26%
🏛️

Balance Sheet (FY 2025)

Total Assets $29.06B
Total Liabilities $43.29B
Stockholders' Equity -$3.27B
Current Assets $29.06B
Current Liabilities $43.29B